As precision medicine in oncology advances, selecting the right genomic analysis method is key to obtaining accurate and actionable insights. Whether detecting MRD, identifying mutations, or developing liquid biopsy assays, the choice between qPCR, targeted NGS, and whole-genome sequencing directly impacts clinical utility.

Speaker: Dale Clash, Strategic Marketing Manager (Molecular)

VIEW THIS WEBINAR TO LEARN ABOUT:

• How qPCR, targeted NGS, and whole-genome sequencing compare in precision medicine applications such as liquid biopsy, MRD monitoring, mutation detection, and hereditary disease screening.
• The advantages and limitations of each approach, including key considerations for
  sensitivity, throughput, cost, and data requirements.
• Real-world assay examples demonstrating how these technologies are applied in
  clinical oncology settings.

Join us to gain a deeper understanding of these powerful technologies and how Meridian can support your assay development with innovative solutions tailored to your needs.